Trial Profile
A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Maralixibat (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms CAMEO
- Sponsors Lumena Pharmaceuticals; Mirum Pharmaceuticals; Shire
- 18 May 2023 Results presented in the Mirum Pharmaceuticals Media Release.
- 18 May 2023 According to a Mirum Pharmaceuticals media release, data from the study was published in Hepatology Communications.
- 01 Oct 2019 According to a Mirum Pharmaceuticals media release, results from this study will be presented at The Liver Meeting 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).